Lumos Pharma Corp (LUMO): Rega marang dodolan

Logo korporat perusahaan Lumos Pharma Corp (LUMO)

The revenue multiple level helps identify asset overvaluation in a timely manner, while 16.90 determines this specific parameter level. The market has already priced in the lack of profit while awaiting the results of final tests. The Lumos Pharma, Inc. (LUMO) strategy is based on capturing market share via the LUM-201 oral stimulant. Creating a treatment system for endocrine pathologies replaces injections with convenient tablets in pediatrics.

Lumos Pharma - Multiplikator P/S LUMO (periode 04.07.2022 - 21.12.2024)

Rincian metrik lan analitis perusahaan lumos-pharma.com (LUMO)

- rega saiki lan proyeksi nilai saham:
Analisis fundamental perusahaan:Lumos Pharma Corp LUMO
Barang utama Lumos Pharma, Inc.

For Lumos Pharma, Inc. (LUMO), which specializes in rare endocrine pathologies, this ratio serves as a tool to compare market capitalization with actual sales volume. By analyzing the company's P/S ratio, an investor assesses the cost of one dollar of revenue, which is particularly critical when outsourcing production to CMO facilities, as low capital expenditures enhance the fundamental efficiency and scalability of the business.

Karo sapa Lumos Pharma, Inc. saingan

Rasio rega marang pendapatan ASND (Ascendis Pharma AS)|Rasio rega marang pendapatan madrigalpharma.com MDGL|Corcept Therapeutics Corp (CORT) - Rega marang dodolan|RYTM - Rasio rega marang pendapatan|AKRO: Rasio rega marang pendapatan|MTSR: Multiplikator P/S|MLTX - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Crinetics Corp|NewAmsterdam Pharma Corp (NAMS) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan soleno.life (SLNO)|Kapitalisasi marang pendapatan Amicus Therapeutics FOLD|Rasio kapitalisasi pasar marang pendapatan 89bio Inc|Multiplikator P/S Agios Pharmaceuticals, Inc. AGIO|GPCR: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan MiMedx Corp MDXG|RZLT (Rezolute Corp) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan LXRX|MBX (MBX Biosciences) - Multiplikator P/S|Kapitalisasi marang pendapatan Altimmune Inc (ALT)|Kapitalisasi marang pendapatan AARD (Aardvark Therapeutics Corp)|Kapitalisasi marang pendapatan Sagimet SGMT|Multiplikator P/S BIOA (BioAge Labs)|Multiplikator P/S Biomea Fusion BMEA|QNCX: Kapitalisasi marang pendapatan|GUTS: Rasio rega marang pendapatan|vTv Therapeutics Inc (VTVT) - Rasio rega marang pendapatan|ATPC: Kapitalisasi marang volume dodolan|PLUR (pluri-biotech.com) - Multiplikator P/S|SYBX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S LPCN|Koefisien rega marang pendapatan Matinas BioPharma Holdings, Inc.|Rasio rega marang pendapatan Spruce Biosciences Inc. SPRB|GLTO - Kapitalisasi marang pendapatan|CTCX - Rasio rega marang pendapatan|ONVO: Rasio rega marang pendapatan|Radius Recycling (RDUS) - Rasio rega marang pendapatan